Table 5.
Variable | Imidafenacin | Solifenacin | ||
---|---|---|---|---|
Number of subjects | 11 | 14 | ||
Residual urine volume (mL) | ||||
0 week | (Mean ± SD) | 15.1 ± 14.7 | 13.4 ± 11.0 | |
4 week | (Mean ± SD) | 30.9 ± 20.4* | 38.6 ± 32.1** | NS |
12 week | (Mean ± SD) | 30.7 ± 28.0 | 30.6 ± 27.7* | NS |
52 week | (Mean ± SD) | 20.6 ± 25.4 | 31.1 ± 23.4** | NS |
QT interval (ms) | ||||
0 week | (Mean ± SD) | 413.6 ± 24.6 | 426.9 ± 22.4 | |
4 week | (Mean ± SD) | 415.8 ± 18.9 | 426.2 ± 20.1 | NS |
12 week | (Mean ± SD) | 416.4 ± 18.4 | 427.2 ± 23.0 | NS |
52 week | (Mean ± SD) | 417.0 ± 20.3 | 424.4 ± 22.5 | NS |
Intragroup (versus 0 weeks: the end of the observation period)
Paired t-test *: P < 0.05, **: P < 0.01
Intergroup: Unpaired t-test, NS: not significant, SD: standard deviation.